What are Wixela and Trelegy, and what do they treat?
Wixela Inhub and Trelegy Ellipta are both inhaled medicines used to manage chronic respiratory conditions, but they aren’t the same regimen.
Wixela Inhub is an inhaled combination of an inhaled corticosteroid (fluticasone) plus a long-acting beta agonist (salmeterol). It’s used for maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma, depending on the prescribed product and dosing.
Trelegy Ellipta combines three medicines in one inhaler: an inhaled corticosteroid (fluticasone furoate), a long-acting beta agonist (vilanterol), and a long-acting muscarinic antagonist (umeclidinium). Trelegy is used for COPD and for asthma in eligible patients (based on the prescribed indication and eligibility criteria).
What’s the key difference in dosing and “how many drugs” you’re getting?
The biggest practical difference is the number of drug classes in the inhaler:
- Wixela delivers two drug classes (an ICS + LABA).
- Trelegy delivers three drug classes (ICS + LABA + LAMA).
If a person still has symptoms or exacerbations on an ICS/LABA regimen, clinicians sometimes step up to a triple-therapy option like Trelegy. The right choice depends on diagnosis (COPD vs asthma), symptom control, exacerbation history, and side-effect considerations.
How do they compare for COPD control?
For COPD, many clinicians use a step-up approach. Because Trelegy includes a LAMA in addition to ICS/LABA, it can provide broader bronchodilation and may reduce exacerbations for some patients compared with an ICS/LABA inhaler alone.
Wixela can be appropriate for COPD patients who are managed with ICS/LABA-based therapy, but it does not add the long-acting muscarinic component.
Your prescriber’s decision typically hinges on whether you’ve had COPD exacerbations, how well symptoms are controlled, and whether you are on the lowest effective steroid dose.
How do they compare for asthma control?
For asthma, the comparison also often comes down to step therapy and patient history. Trelegy’s triple mechanism may be considered for patients whose asthma is not adequately controlled on an ICS/LABA regimen, while Wixela is the simpler option (ICS/LABA).
Asthma therapy decisions are also strongly tied to inhaler technique, adherence, trigger control, and your personal exacerbation history.
What side effects are most likely with each?
Both medicines share corticosteroid and long-acting bronchodilator effects, but Trelegy adds a muscarinic antagonist.
Common steroid-related concerns include oral thrush and hoarseness, so rinsing after inhalation is often recommended.
Common bronchodilator-related concerns can include tremor or palpitations (from LABA effects) and dry mouth (from LAMA effects). Your risk profile depends on dose, other medications, and your medical history.
Are they interchangeable?
They generally aren’t considered interchangeable in a direct, one-for-one way because they contain different drug combinations and different dosing formats.
Switching between them usually means stepping up or down in therapy intensity (especially because Trelegy is triple therapy). Any change should be done only under clinician guidance.
Which is usually cheaper or more likely to be covered?
Coverage and cost vary a lot by insurance plan, pharmacy formulary, and whether you qualify for discounts or assistance programs. In the U.S., inhaler pricing can differ significantly even when two products are used for similar purposes.
If you tell me your country and (if you’re in the U.S.) your insurance type (Medicare/Commercial) and the dose you were prescribed, I can help you think through what to ask your pharmacy about.
What should patients ask their clinician when choosing between them?
Patients typically get the clearest answers by asking:
- Whether the goal is COPD control, asthma control, or both.
- Whether symptoms/exacerbations justify moving from dual therapy (Wixela) to triple therapy (Trelegy).
- How long to try the current regimen and what improvement counts as “working.”
- What side effects matter most for them (thrush/hoarseness, tremor/palpitations, dry mouth) and how to mitigate them.
- Whether they’re taking the correct dose and using proper inhaler technique.
If you share whether you’re comparing for COPD or asthma (and what dose of Wixela and what Trelegy strength you have), I can tailor the comparison to your situation.